Sign In
Last checked at 
9 Jun 2025 16:37
BIOPHARMA CREDIT PLC
(THE "COMPANY")
RESULT OF 2025 ANNUAL GENERAL MEETING
The Company is pleased to announce that, at the Annual General Meeting held today, all resolutions put to the meeting were passed by way of a poll.
Resolutions | Votes For | % | Votes Against | % | Total Votes | % of Total Voting Rights Voted | Votes Withheld1 |
1: To approve the continuation resolution | 570,318,209 | 99.44% | 3,188,644 | 0.56% | 573,506,853 | 50.78% | 10,524,548 |
2: To receive and accept the annual report and financial statements | 565,083,635 | 100.00% | 5,172 | 0.00% | 565,088,807 | 50.04% | 18,942,594 |
3: To approve the Directors' Remuneration Report | 579,743,647 | 99.96% | 225,063 | 0.04% | 579,968,710 | 51.36% | 4,062,691 |
4: To re-elect Harry Hyman as a Director | 501,932,822 | 96.85% | 16,347,475 | 3.15% | 518,280,297 | 45.89% | 65,751,104 |
5: To re-elect Colin Bond as a Director | 574,657,924 | 99.07% | 5,390,941 | 0.93% | 580,048,865 | 51.36% | 3,982,536 |
6: To re-elect Duncan Budge as a Director | 580,031,390 | 100.00% | 17,475 | 0.00% | 580,048,865 | 51.36% | 3,982,536 |
7: To re-elect Stephanie Léouzon as a Director | 580,037,743 | 100.00% | 11,122 | 0.00% | 580,048,865 | 51.36% | 3,982,536 |
8: To re-elect Sapna Shah as a Director | 580,037,743 | 100.00% | 11,122 | 0.00% | 580,048,865 | 51.36% | 3,982,536 |
9: To re-elect Rolf Soderstrom as a Director | 580,037,743 | 100.00% | 11,122 | 0.00% | 580,048,865 | 51.36% | 3,982,536 |
10: To re-appoint Ernst & Young LLP as Auditor to the Company | 579,899,832 | 99.97% | 196,131 | 0.03% | 580,095,963 | 51.37% | 3,935,438 |
11: To authorise the Directors to determine the remuneration of the Auditor | 580,008,675 | 100.00% | 21,228 | 0.00% | 580,029,903 | 51.36% | 4,001,498 |
12: To approve the Company's dividend payment policy | 580,095,804 | 100.00% | 239 | 0.00% | 580,096,043 | 51.37% | 3,935,358 |
13: To authorise the allotment of shares by the Company | 579,965,234 | 99.98% | 136,051 | 0.02% | 580,101,285 | 51.37% | 3,930,116 |
14: To authorise the disapplication of pre-emption rights | 579,892,518 | 99.97% | 169,790 | 0.03% | 580,062,308 | 51.36% | 3,969,093 |
15: To authorise the Company to make market purchases of ordinary shares | 580,088,531 | 100.00% | 13,932 | 0.00% | 580,102,463 | 51.37% | 3,928,938 |
16: To authorise the Company to hold general meetings on 14 clear days' notice | 580,056,976 | 99.99% | 38,281 | 0.01% | 580,095,257 | 51.37% | 3,936,144 |
1. A 'vote withheld' is not a vote under English law and is not counted in the calculation of votes 'for' or 'against' a resolution.
Copies of resolutions 13 to 16 have been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
9 June 2025
Enquiries:
BioPharma Credit plc
via MUFG Corporate Governance Limited
Company Secretary
+44 (0) 333 300 1932
Burson Buchanan
Mark Court / Jamie Hooper / Henry Wilson / Nick Croysdill
+44 (0)20 7466 5000
biopharmacredit@buchanan.uk.com
Notes to Editors:
BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.
LEI: 213800AV55PYXAS7SY24
Follow the stocks
